SK282512B6 - 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-9-oxo-19-nor- cyclopropa[g]tax-11-en-13alpha-yl-(2r,3s)-3-tert-butoxycarbonylam ino-2-hydroxy-3-phenylpropionate dihydrate and its preparation me thod - Google Patents
4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-9-oxo-19-nor- cyclopropa[g]tax-11-en-13alpha-yl-(2r,3s)-3-tert-butoxycarbonylam ino-2-hydroxy-3-phenylpropionate dihydrate and its preparation me thod Download PDFInfo
- Publication number
- SK282512B6 SK282512B6 SK790-98A SK79098A SK282512B6 SK 282512 B6 SK282512 B6 SK 282512B6 SK 79098 A SK79098 A SK 79098A SK 282512 B6 SK282512 B6 SK 282512B6
- Authority
- SK
- Slovakia
- Prior art keywords
- hydroxy
- cyclopropa
- benzoyloxy
- tax
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Vynález sa týka dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-5P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-l l-én-13a-yl-(2R,3S)-3-/erc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu a jeho prípravy.The invention relates to 4,10β-diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa dihydrate [g] tax-11-en-13a-yl- (2R, 3S) -3- tert -Butoxycarbonylamino-2-hydroxy-3-phenylpropionate and its preparation.
Doterajší stav technikyBACKGROUND OF THE INVENTION
4,10P-Diacetoxy-2a-benzoyloxy-5P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3S)-3-terc-butoxykarbonylamino-2-hydroxy-3-fenylpropionát má pozoruhodné protirakovinové a protileukemické vlastnosti.4,10β-Diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- (2R, 3S) -3- tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate has remarkable anti-cancer and anti-leukemic properties.
4,10P-Diacetoxy-2a-benzoyloxy-53,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13cx-yl-(2R,3S)-3-terc-butoxykarbonylamino-2-hydroxy-3-fenylpropionát sa pripraví spôsobom, ktorý je opísaný najmä v medzinárodnej prihláške PCT WO 94/13654.4,10 β-Diacetoxy-2α-benzoyloxy-53,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13cx-yl- (2R, 3S) -3- tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate is prepared according to the method described in particular in PCT International Application WO 94/13654.
Zistilo sa, že dihydrát 4,10fi-diacetoxy-2a-benzoyloxy-5 [1,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13 a-yl-(2R,3S)-3 -Zerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu má výrazne vyššiu stabilitu ako rovnaký produkt v bezvodej forme.It has been found that 4,10f-diacetoxy-2a-benzoyloxy-5 [1,2,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13-a-yl- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate has significantly higher stability than the same product in anhydrous form.
Podstata vynálezuSUMMARY OF THE INVENTION
Podľa vynálezu sa môže dihydrát 4,10[]-diacetoxy-2a-benzoyloxy-5 p,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-l 1 -én-13a-yl-(2R,3 S)-3-ŕerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu získať kryštalizáciou 4,10p-diacetoxy-2a-benzoyloxy-5p,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu alebo rekryštalizáciou dihydrátu zo zmesi vody a alifatického alkoholu obsahujúceho 1 až 3 atómy uhlíka alebo zo zmesi vody a ketónu obsahujúceho 3 až 4 atómy uhlíka a následným vysušením izolovaného produktu pri zníženom tlaku a prípadným udržiavaním tohto produktu v prostredí s relatívnou vlhkosťou vyššou alebo rovnajúcou sa 40 % alebo priamym vysušením v atmosfére, ktorej relatívna vlhkosť je vyššia alebo sa rovná 40 %.According to the invention, 4,10 [] - diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl dihydrate can be used. - (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate obtain by crystallization of 4,10β-diacetoxy-2a-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor -cyclopropa [g] tax-11-en-13a-yl- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate or by recrystallization of the dihydrate from a mixture of water and an aliphatic alcohol containing 1 to 3 carbon atoms, or from a mixture of water and a ketone containing 3 to 4 carbon atoms and subsequently drying the isolated product under reduced pressure and optionally maintaining the product in an environment with a relative humidity greater than or equal to 40% or by direct drying in an atmosphere greater than or equal to 40 %.
Po uskutočnení spôsobu podľa vynálezu môže byť obzvlášť výhodnéAfter carrying out the process according to the invention it may be particularly advantageous
- uviesť 4,l0P-diacctoxy-2a-bcnzoyloxy-5p,20-cpoxy-l-hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13 a-yl-(2R,3 S)-3 -/erc-butoxykarbonyl amino-2-hydroxy-3 -fenylpropionát alebo jeho hydrát do roztoku v alifatickom alkohole obsahujúcom 1 až 3 atómy uhlíka alebo v ketóne obsahujúcom 3 až 4 atómy uhlíka,- indicate 4,10P-diacethoxy-2a-benzoyloxy-5β, 20-cpoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- (2R, 3S) ) -3- tert -butoxycarbonyl amino-2-hydroxy-3-phenylpropionate or a hydrate thereof in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or in a ketone containing 3 to 4 carbon atoms,
- pridať k získanému roztoku vodu,- add water to the solution obtained,
- iniciovať kryštalizáciu roztoku zárodočnými kryštálmi dihydrátu a potom znovu pridať vodu,- initiate crystallization of the solution by seed crystals of dihydrate and then add water again,
- oddeliť získané kryštály a potom- separate the obtained crystals and then
- vysušiť tieto kryštály pri zníženom tlaku a potom ich prípadne udržiavať v atmosfére, ktorej relatívna vlhkosť je vyššia alebo sa rovná 40 %, čo znamená príkladne pre relatívnu vlhkosť 40 % vysušenie pri reziduálnom tlaku asi 1,33 kPa pre teplotu 25 °C a pri reziduálnom tlaku asi 3,86 kPa pre teplotu 45 °C, alebodrying the crystals under reduced pressure and then optionally maintaining them in an atmosphere having a relative humidity of greater than or equal to 40%, which means, for example, a relative humidity of 40% drying at a residual pressure of about 1.33 kPa at 25 ° C and a residual pressure of about 3,86 kPa for a temperature of 45 ° C; or
- vysušiť kryštály priamo v atmosfére, ktorej relatívna vlhkosť je vyššia alebo sa rovná 40 %, čo znamená príkladne pre relatívnu vlhkosť 40 % vysušenie pri reziduálnom tlaku asi 1,33 kPa pre teplotu 25 °C a pri reziduálnom tlaku asi 3,86 kPa pre teplotu 45 °C.- to dry the crystals directly in an atmosphere having a relative humidity of greater than or equal to 40%, which means, for example, for a relative humidity of 40% drying at a residual pressure of about 1.33 kPa for 25 ° C and a residual pressure of about 3.86 kPa for temperature 45 ° C.
Všeobecne sa 4,10p-diacetoxy-2a-benzoyloxy-5p,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13ct-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionát alebo jeho hydrát rozpustí v nadbytku alifatického alkoholu, výhodne etanolu, alebo v prebytku ketónu, výhodne acetónu. Výhodne množstvo alkoholu alebo ketónu tvorí 4 až 16 objemových dielov, vztiahnuté na hmotnosť použitého 4,10P-diacetoxy-2a-benzoyloxy-5P,20-epoxy-l-hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-Zerc.butoxykarbonylamino-2-hydroxy-3-fény lpropionátu.Generally, 4,10β-diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13-yl- (2R, 3S) - 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate or a hydrate thereof is dissolved in an excess of an aliphatic alcohol, preferably ethanol, or in an excess of a ketone, preferably acetone. Preferably the amount of alcohol or ketone is from 4 to 16 parts by volume, based on the weight of 4,10P-diacetoxy-2α-benzoyloxy-5P, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax- 11-en-13a-yl- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.
Všeobecne sa voda pridáva v takom množstve, aby sa finálny objemový pomer voda/alkohol alebo voda/ketón rovnal 1 : 3 až 3 : 1.Generally, the water is added in an amount such that the final water / alcohol or water / ketone volume ratio is 1: 3 to 3: 1.
Vykryštalizovaný dihydrát 4,10P-diacetoxy-2a-benzoyloxy-53,20-epoxy-l-hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-Zerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu sa potom oddelí, výhodne filtráciou alebo odstredením. Vysušenie alebo prípadne udržiavanie v atmosfére, ktorej relatívna vlhkosť je vyššia alebo sa rovná 40 % sa uskutočňuje pri zníženom tlaku, všeobecne tlaku medzi 0,5 a 30 kPa, výhodne pri tlaku blízkom 5 kPa, pri teplote medzi 10 a 70 °C, výhodne pri teplote blízkej 40 °C.Crystallized 4,10P-diacetoxy-2α-benzoyloxy-53,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa dihydrate [g] tax-11-en-13a-yl- (2R, 3S) - The 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate is then separated, preferably by filtration or centrifugation. Drying or optionally maintaining in an atmosphere whose relative humidity is greater than or equal to 40% is carried out under reduced pressure, generally between 0.5 and 30 kPa, preferably at a pressure close to 5 kPa, at a temperature between 10 and 70 ° C, preferably at a temperature near 40 ° C.
Ďalej sa študovala aktívna izoterma získaného produktu vo vode. V rámci tejto štúdie boli vzorky dihydrátu 4,10β-diacetoxy-2cc-benzoyloxy-5 P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-l l-én-13a-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu úmyselne dehydratované intenzívnym vysušením a potom sa prechovávali v atmosférach s regulovanou relatívnou vlhkosťou (HR) pri teplote 25 °C. Obsahy vody stanovené pomocou ATG ukazujú, že sa produkty stabilizujú na obsahu blízkom 4 % (medzi 3 a 5 %) v prípade, že relatívna vlhkosť je vyššia alebo sa rovná 40 % (pre dihydrát tvorí teoretický obsah vody 4,15 %).Further, the active isotherm of the obtained product in water was studied. In this study, 4,10β-diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl dihydrate samples - (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate deliberately dehydrated by intensive drying and then stored in controlled humidity atmospheres (HR) at 25 ° C. The water contents determined by ATG show that the products stabilize at a content close to 4% (between 3 and 5%) when the relative humidity is greater than or equal to 40% (for the dihydrate it constitutes a theoretical water content of 4.15%).
Výsledky tejto štúdie sú uvedené v nasledujúcej tabuľke.The results of this study are shown in the following table.
Tabuľkatable
Aktivitná izoterma vo vode pri teplote 25 °CActivity isotherm in water at 25 ° C
Pri uskutočňovaní spôsobu podľa vynálezu je možné spracovať priamo etanolový roztok 4,103-diacetoxy-2a-benzoyloxy-5P,20-epoxy-l-hydroxy-9-oxo-19-nor-cyklopropa[g]tax-1 l-én-13a-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu získaný po deprotekcii v kyslom prostredí 4,10f3-diacctoxy-2a-benzoyloxy-5p,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 - é n-13a-yl-(2R,4S,5R)-3-Zerc-butoxykarbonyl-2-(4-metoxyfenyl)-4-fenyloxazolidín-5-karboxyIátu.In carrying out the process of the invention, ethanol solution of 4,103-diacetoxy-2a-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-ene-13a- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate obtained after acid deprotection of 4,10f3-diacethoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo -19-nor-cyclopropa [g] tax-11-en-13a-yl- (2R, 4S, 5R) -3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyloxazolidine-5-carboxylate.
V nasledujúcej časti opisu bude vynález bližšie objasnený pomocou konkrétnych príkladov jeho uskutočnenia, pričom tieto príklady majú len ilustračný charakter a nijako neobmedzujú rozsah vynálezu, ktorý je jednoznačne vymedzený formuláciou patentových nárokov.In the following, the invention will be explained in more detail by means of specific examples thereof, the examples being illustrative only and in no way limiting the scope of the invention, which is clearly defined by the wording of the claims.
Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION
Príklad 1Example 1
Do trojhrdlovej banky sa zavedú 2 g surového 4,10β-diacetoxy-2a-benzoyloxy-5 β ,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-Zerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu a 20 cm3 absolútneho etanolu. Získaný roztok sa mieša pri teplote 50 °C, následne sa k nemu pridá v priebehu 45 minút 20 cm3 vody a získaná suspenzia sa ochladí na teplotu blízku 20 °C. Po filtrácii sa produkt na filtri premyje 20 cm3 zmesi absolútneho etanolu a vody v objemovom pomere 1:1, následne sa produkt vysuší pri teplote 40 °C a pri zníženom tlaku (5,3 kPa), Získa sa 1,64 g dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-5 β,20-εροχγ-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu obsahujúceho (stanovené pomocou ATG) 3,8 % vody (teoretická hodnota obsahu vody v dihydráte je 4,15 %). Dosiahnutý výťažok: asi 80 %2 g of crude 4,10β-diacetoxy-2a-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl are introduced into a three neck flask. - (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and 20 cm 3 of absolute ethanol. The solution obtained is stirred at a temperature of 50 ° C, then 20 cm 3 of water are added over 45 minutes and the suspension obtained is cooled to a temperature in the region of 20 ° C. After filtration, the product on the filter with 20 cm 3 absolute ethanol: water in a ratio of 1: 1, then the product was dried at 40 DEG C. under reduced pressure (5.3 kPa), to give 1.64 g dihydrate 4 10β-diacetoxy-2α-benzoyloxy-5β, 20-εροχγ-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- (2R, 3S) -3- tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate containing (determined by ATG) 3.8% water (theoretical value of the water content of the dihydrate is 4.15%). Yield achieved: about 80%
Diagram DPRX (práškový rôntgenogram) ukazuje, že takto získaný produkt má skutočne charakteristiky dihydrátu.The DPRX (powder X-ray) diagram shows that the product thus obtained has indeed dihydrate characteristics.
Prášková rôntgenografia sa uskutočnila s použitím zariadenia Philips PW 1700 s výbojkou s kobaltovou antikatódou (lambda Ka = 1,7889 Ä), snímanie sa uskutočnilo pod východiskovým snímacím uhlom 5° 2-0, finálne snímanie 40° 2-0, krok = 0,02° 2-θ, 1 s per krok, kremíková pastilka.Powder X-ray was performed using a Philips PW 1700 cobalt anticatode lamp (lambda Ka = 1.7889 Å), scanning was performed at an initial scan angle of 5 ° 2-0, final scan 40 ° 2-0, step = 0, 02 ° 2-θ, 1 sec per step, silicon lozenge.
Termogravimetrická analýza (ATG) sa uskutočnila s použitím termováhy Perkin-Elmer TGA 7 pri východiskovej teplote 25 °C a finálnej teplote 300 °C s teplotným gradientom 10 °C za minútu.Thermogravimetric analysis (ATG) was performed using a Perkin-Elmer TGA 7 thermal balance at a starting temperature of 25 ° C and a final temperature of 300 ° C with a temperature gradient of 10 ° C per minute.
Príklad 2Example 2
Do reaktora prepláchnutého dusíkom sa zavedie 515 g dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-5 p,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3S)-3-Zerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu v surovom stave a 4 litre absolútneho etanolu. Získaná suspenzia sa zohrieva na teplotu 35 až 40 °C až do okamihu, keď dôjde k rozpusteniu pevného podielu a reaktor sa potom prevedie na režim zníženého tlaku 8 kPa. Oddestiluje sa asi 8 litrov rozpúšťadla, pričom sa udržuje konštantný objem v reaktore kontinuálnym privádzaním etanolu (8 litrov) do reaktora. Po prevedení reaktora do režimu atmosférického tlaku sa roztok vyčerí prechodom cez filter vybavený filtračnou plachietkou s veľkosťou ôkThe nitrogen purged reactor was charged with 515 g of 4,10β-diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa dihydrate [g] tax-11-ene-13a- (2R, 3S) -3-tert-Butoxycarbonylamino-2-hydroxy-3-phenylpropionate in crude form and 4 L of absolute ethanol. The suspension obtained is heated to 35-40 ° C until the solids dissolve and the reactor is then brought to a reduced pressure mode of 8 kPa. About 8 liters of solvent are distilled off while maintaining a constant volume in the reactor by continuously feeding ethanol (8 liters) to the reactor. After the reactor has been brought to atmospheric pressure, the solution is clarified by passing through a filter equipped with a mesh cloth
0,45 pm. Po prepláchnutí filtra jedným litrom absolútneho etanolu sa v priebehu jednej hodiny pri teplote 40 °C k celkovému kvapalnému podielu pridá asi 1,8 litrov vody. Po iniciácii kryštalizácie roztoku pridaním 8 g zárodočných kryštálov dihydrátu 4,lOP-diacetoxy-2a-benzoyloxy-50,2O-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3S)-3-Zerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu sa získaná zmes ochladí v priebehu 15 hodín na teplotu blízku 20 °C. Suspenzia sa potom zohreje na teplotu 40 °C, následne sa k nej pridá v priebehu 4 hodín 1,66 litrov vody. Zmes sa ochladí na teplotu blízku 20 °C a mieša sa počas 17 hodín. Suspenzia sa sfiltruje cez sklenenú fritu a produkt sa odstredí a premyje 1,25 litra zmesi alkoholu a vody v objemovom pomere 50 : 50. Produkt sa potom vysuší v sušiarni pri teplote 35 °C a tlaku 5,3 kPa a v priebehu 72 hodín v prítomnosti zásoby vody a potom pri teplote 35 °C a tlaku 2,7 kPa v priebehu 8 hodín v neprítomnosti zásoby vody a potom znovu pri teplote 35 °C a tlaku 5,3 kPa v priebehu 16 hodín a v prítomnosti zásoby vody.0.45 pm. After rinsing the filter with one liter of absolute ethanol, about 1.8 liters of water was added to the total liquid portion at 40 ° C over one hour. After initiating crystallization of the solution by adding 8 g of seed crystals of 4, 10-D-diacetoxy-2a-benzoyloxy-50,2O-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa dihydrate [g] tax-11-en-13a- yl (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate was cooled to a temperature in the region of 20 ° C over 15 hours. The slurry was then heated to 40 ° C and 1.66 L of water was added over 4 hours. The mixture was cooled to a temperature in the region of 20 ° C and stirred for 17 hours. The suspension is filtered through a glass frit and the product is centrifuged and washed with 1.25 liters of a 50:50 alcohol / water mixture. The product is then dried in an oven at 35 ° C and 5.3 kPa and for 72 hours in the presence of water at a temperature of 35 ° C and a pressure of 2.7 kPa for 8 hours in the absence of a water supply and then again at 35 ° C at a pressure of 5.3 kPa for 16 hours and in the presence of a water supply.
Takto sa získa 491 g dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-53,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-l l-én-13a-yl-(2R,3S)-3-/erc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu obsahujúceho 4,0 % vody (Karí Fisher). Diagram DPRX (práškový rôntgenogram) ukazuje, že takto získaný produkt má formu dihydrátu (teoretická hodnota obsahu vody dihydrátu 4, ΙΟβ-diacetoxy-2a-benzoyloxy-5 P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu tvorí 4,15%).There was thus obtained 4,10 [beta] -diacetoxy-2a-benzoyloxy-53,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- (491 g) dihydrate. 2R, 3S) -3- tert -butoxycarbonylamino-2-hydroxy-3-phenylpropionate containing 4.0% water (Curie Fisher). The DPRX (powder X-ray) diagram shows that the product thus obtained is in the form of a dihydrate (theoretical water content of dihydrate 4, β-diacetoxy-2a-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor- cyclopropa [g] tax-11-en-13a-yl- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate accounts for 4.15%).
Prášková rôntgenografia sa uskutočnila v podmienkach opísaných v príklade 1.The powder X-ray was performed under the conditions described in Example 1.
Príklad 3Example 3
Do trojhrdlovej banky sa zavedú 2 g surového 4,10β-diacetoxy-2a-benzoyloxy-5 β,20-εροχγ-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3 S)-3-terc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu a 20 cm3 acetónu. K získanému roztoku, ktorý sa mieša pri teplote blízkej 20 °C, sa v priebehu 35 minút pridá asi 20 cm3 vody. Získaná suspenzia sa mieša počas asi 15 minút. Po filtrácii sa produkt premyje na filtri dvakrát 20 cm3 zmesi acetónu a vody v objemovom pomere 1:1, následne sa produkt vysuší pri teplote 40 °C a pri zníženom tlaku (5,3 kPa). Takto sa získa sa 1,28 g dihydrátu 4,10β-diacetoxy-2a-bcnzoyloxy^5,20-epoxy-l-hydroxy-9-oxo-19-nor-cyklopropa[g]tax-11 -én-13a-yl-(2R,3 S)-3-íerc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu. Dosiahnutý výťažok tvorí asi 75 %.2 g of crude 4,10β-diacetoxy-2a-benzoyloxy-5β, 20-εροχγ-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl are introduced into a three-necked flask. - (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and 20 cm 3 of acetone. About 20 cm 3 of water are added over 35 minutes to the solution obtained, which is stirred at a temperature in the region of 20 ° C. The resulting suspension is stirred for about 15 minutes. After filtration, the product is washed on the filter with twice 20 cm 3 of acetone: water at a volume ratio of 1: 1, then the product was dried at 40 DEG C. under reduced pressure (5.3 kPa). 1.28 g of 4,10β-diacetoxy-2a-benzoyloxy-5,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl dihydrate is thus obtained. - (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate. The yield obtained is about 75%.
Diagram DPRX (práškový rôntgenogram) ukazuje, že takto získaný produkt má charakteristiky dihydrátu.The DPRX (powder X-ray) diagram shows that the product thus obtained has the characteristics of a dihydrate.
Prášková rôntgenografia sa uskutočnila v podmienkach opísaných v príklade 1.The powder X-ray was performed under the conditions described in Example 1.
Príklad 4Example 4
Do reaktora prepláchnutého dusíkom sa zavedie 120 g 4,10P-diacetoxy-2a-benzoyloxy-5fi,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,4S,5R)-3-/erc-butoxykarbonyl-2-(4-metoxyfenyl)-4-fenyloxazolidín-5-karboxylátu a 1,08 litra etylacetátu. Suspenzia sa mieša pri teplote blízkej 20 °C, následne sa do reaktora zavedie roztok 3,25 cm3 36 % kyseliny chlorovodíkovej v 17,6 cm3 vody. Po 3 hodinách a 30 minútach sa do reaktora zavedie roztok 3,5 g hydrogenuhličitanu sodného v 350 cm3 vody a získaný roztok sa mieša počas 15 minút. Po dekantácii a odtiahnutí vodnej fázy sa uskutoční dvojaké premytie vždy 350 cm3 vody. Organická fáza sa zahustí pri zníženom tlaku pri teplote asi 25 °C až sa dosiahne zvyškový objem 350 cm3, následne sa pridá 350 cm3 absolútneho etanolu. Uskutoční sa destilácia pri zníženom tlaku pri teplote asi 30 °C až k vyčerpaniu etylacetátu, pričom sa zavedie 1,5 litra absolútneho etanolu. Roztok sa zohreje na teplotu 40 °C, následne sa v priebehu 15 minút pridá 470 cm3 vody. Kryštalizácia roztoku sa iniciuje pridaním suspenzie 1 g dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-5 P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g] tax-11 -én-13a-yl-(2R,3 S)-3-terc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu v zmesi 40 cm3 vody a 40 cm3 absolútneho etanolu. Po 15 hodinách pri teplote asi 40 °C sa v priebehu 4 až 5 hodín pridá 410 cm3 vody, následne sa suspenzia ochladí na teplotu 20 °C. Po filtrácii a premytí produktu na filtri sa produkt suší počas 15 hodín pri zníženom tlaku (2,7 kPa) a pri teplote 25 °C a potom ešte počas 24 hodín pri teplote 35 °C.120 g of 4,10P-diacetoxy-2α-benzoyloxy-5α, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- are introduced into a nitrogen purged reactor. (2R, 4S, 5R) -3- tert -Butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyloxazolidine-5-carboxylate and 1.08 L of ethyl acetate. The suspension is stirred at a temperature in the region of 20 DEG C. and a solution of 3.25 cm @ 3 of 36% hydrochloric acid in 17.6 cm @ 3 of water is introduced into the reactor. After 3 hours and 30 minutes, a solution of 3.5 g of sodium bicarbonate in 350 cm @ 3 of water is introduced into the reactor and stirred for 15 minutes. After decantation and removal of the aqueous phase, two washes of 350 cm @ 3 of water are carried out. The organic phase is concentrated under reduced pressure at a temperature of about 25 ° C until a residual volume of 350 cm 3 is reached, followed by the addition of 350 cm 3 of absolute ethanol. Distillation is carried out under reduced pressure at a temperature of about 30 [deg.] C. until ethyl acetate is exhausted, 1.5 l of absolute ethanol being introduced. The solution is heated to 40 ° C, then 470 cm 3 of water are added over 15 minutes. Crystallization of the solution is initiated by the addition of a suspension of 1 g of 4,10β-diacetoxy-2a-benzoyloxy-5β, 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa dihydrate [g] tax-11-ene-13a- yl (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate in a mixture of 40 cm 3 of water and 40 cm 3 of absolute ethanol. After 15 hours at a temperature of about 40 ° C, 410 cm 3 of water are added over a period of 4 to 5 hours, then the suspension is cooled to 20 ° C. After filtration and washing of the product on the filter, the product is dried for 15 hours under reduced pressure (2.7 kPa) at 25 ° C and then for 24 hours at 35 ° C.
Takto sa získa 102 g dihydrátu 4,10P-diacetoxy-2a-benzoyloxy-5 P,20-epoxy-1 -hydroxy-9-oxo-19-nor-cyklopropa[g]tax-ll-én-13a-yl-(2R,3S)-3-terc-butoxykarbonylamino-2-hydroxy-3-fenylpropionátu obsahujúceho 4,3 % vody (Karí Fisher).102 g of 4,10 [beta] -diacetoxy-2a-benzoyloxy-5 [beta], 20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa [g] tax-11-en-13a-yl- are thus obtained. 2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate containing 4.3% water (Curry Fisher).
Výťažok produktu tvorí asi 93 %.The product yield is about 93%.
Diagram DPRX (práškový rontgenogram) ukazuje, že takto získaný produkt má charakteristiky dihydrátu.The DPRX (powder X-ray) diagram shows that the product so obtained has dihydrate characteristics.
Prášková rontgenografia sa uskutočňuje v podmienkach opísaných v príklade 1.Powder x-ray is performed under the conditions described in Example 1.
Claims (6)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9514841A FR2742438B1 (en) | 1995-12-14 | 1995-12-14 | (2R, 3S) DIHYDRATE -3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY- 3-PHENYLPROPIONATE OF 4,10BETA-DIACETOXY-2ALPHA-BENZOYLOXY- 5BETA, 2O-EPOXY-1-HYDROX CYCLOPROPA (G) TAX-11- ENE-13ALPHA-YLE, AND PREPARATION METHOD THEREOF |
PCT/FR1996/001957 WO1997021695A1 (en) | 1995-12-14 | 1996-12-09 | 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME |
Publications (2)
Publication Number | Publication Date |
---|---|
SK79098A3 SK79098A3 (en) | 1998-11-04 |
SK282512B6 true SK282512B6 (en) | 2002-10-08 |
Family
ID=9485512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK790-98A SK282512B6 (en) | 1995-12-14 | 1996-12-09 | 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-9-oxo-19-nor- cyclopropa[g]tax-11-en-13alpha-yl-(2r,3s)-3-tert-butoxycarbonylam ino-2-hydroxy-3-phenylpropionate dihydrate and its preparation me thod |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP0876361B1 (en) |
JP (1) | JP4059351B2 (en) |
KR (1) | KR100429330B1 (en) |
CN (1) | CN101113143A (en) |
AR (1) | AR004380A1 (en) |
AT (1) | ATE204573T1 (en) |
AU (1) | AU713086C (en) |
BG (1) | BG63010B1 (en) |
BR (1) | BR9611957A (en) |
CA (1) | CA2236545C (en) |
CO (1) | CO4810227A1 (en) |
CZ (1) | CZ288998B6 (en) |
DE (1) | DE69614716T2 (en) |
DK (1) | DK0876361T3 (en) |
DZ (1) | DZ2140A1 (en) |
EA (1) | EA000668B1 (en) |
ES (1) | ES2162123T3 (en) |
FR (1) | FR2742438B1 (en) |
GR (1) | GR3036437T3 (en) |
HU (1) | HU224962B1 (en) |
IL (1) | IL124766A (en) |
IN (1) | IN185809B (en) |
MY (1) | MY115886A (en) |
NO (1) | NO317356B1 (en) |
NZ (1) | NZ323964A (en) |
OA (1) | OA11012A (en) |
PL (1) | PL187613B1 (en) |
PT (1) | PT876361E (en) |
RO (1) | RO115880B1 (en) |
SK (1) | SK282512B6 (en) |
TN (1) | TNSN96157A1 (en) |
TR (1) | TR199801087T2 (en) |
TW (1) | TW358093B (en) |
UA (1) | UA55401C2 (en) |
UY (1) | UY24387A1 (en) |
WO (1) | WO1997021695A1 (en) |
ZA (1) | ZA9610200B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102851740A (en) * | 2011-06-30 | 2013-01-02 | 复旦大学 | Fluorinated docetaxel crystal and its preparation method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698871B1 (en) * | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | New taxoids, their preparation and the pharmaceutical compositions containing them. |
-
1995
- 1995-12-14 FR FR9514841A patent/FR2742438B1/en not_active Expired - Fee Related
-
1996
- 1996-09-12 UA UA98063068A patent/UA55401C2/en unknown
- 1996-12-02 UY UY24387A patent/UY24387A1/en not_active IP Right Cessation
- 1996-12-04 TW TW085114946A patent/TW358093B/en not_active IP Right Cessation
- 1996-12-04 ZA ZA9610200A patent/ZA9610200B/en unknown
- 1996-12-09 AT AT96941720T patent/ATE204573T1/en active
- 1996-12-09 DZ DZ960185A patent/DZ2140A1/en active
- 1996-12-09 DE DE69614716T patent/DE69614716T2/en not_active Expired - Lifetime
- 1996-12-09 EP EP96941720A patent/EP0876361B1/en not_active Expired - Lifetime
- 1996-12-09 AU AU11013/97A patent/AU713086C/en not_active Ceased
- 1996-12-09 WO PCT/FR1996/001957 patent/WO1997021695A1/en active IP Right Grant
- 1996-12-09 RO RO98-01069A patent/RO115880B1/en unknown
- 1996-12-09 DK DK96941720T patent/DK0876361T3/en active
- 1996-12-09 JP JP52179097A patent/JP4059351B2/en not_active Expired - Fee Related
- 1996-12-09 CN CNA2007101024535A patent/CN101113143A/en active Pending
- 1996-12-09 BR BR9611957A patent/BR9611957A/en not_active IP Right Cessation
- 1996-12-09 KR KR10-1998-0704420A patent/KR100429330B1/en not_active IP Right Cessation
- 1996-12-09 HU HU9904048A patent/HU224962B1/en not_active IP Right Cessation
- 1996-12-09 CA CA002236545A patent/CA2236545C/en not_active Expired - Fee Related
- 1996-12-09 PT PT96941720T patent/PT876361E/en unknown
- 1996-12-09 SK SK790-98A patent/SK282512B6/en not_active IP Right Cessation
- 1996-12-09 TR TR1998/01087T patent/TR199801087T2/en unknown
- 1996-12-09 EA EA199800452A patent/EA000668B1/en not_active IP Right Cessation
- 1996-12-09 ES ES96941720T patent/ES2162123T3/en not_active Expired - Lifetime
- 1996-12-09 PL PL96327451A patent/PL187613B1/en not_active IP Right Cessation
- 1996-12-09 NZ NZ323964A patent/NZ323964A/en not_active IP Right Cessation
- 1996-12-09 IL IL12476696A patent/IL124766A/en not_active IP Right Cessation
- 1996-12-09 CZ CZ19981830A patent/CZ288998B6/en not_active IP Right Cessation
- 1996-12-12 IN IN2788DE1996 patent/IN185809B/en unknown
- 1996-12-13 AR ARP960105668A patent/AR004380A1/en active IP Right Grant
- 1996-12-13 TN TNTNSN96157A patent/TNSN96157A1/en unknown
- 1996-12-13 CO CO96065734A patent/CO4810227A1/en unknown
- 1996-12-13 MY MYPI96005258A patent/MY115886A/en unknown
-
1998
- 1998-06-04 NO NO19982561A patent/NO317356B1/en not_active IP Right Cessation
- 1998-06-12 BG BG102535A patent/BG63010B1/en unknown
- 1998-06-15 OA OA9800085A patent/OA11012A/en unknown
-
2001
- 2001-08-23 GR GR20010400773T patent/GR3036437T3/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011254654B2 (en) | Process for the preparation of chiral triazolones | |
KR100377159B1 (en) | Method for preparing Form 2 of clarithromycin without residual solvent | |
CZ125495A3 (en) | Process for preparing clavulanic acid and salt thereof | |
US4775751A (en) | Process for cephalexin hydrochloride alcoholates | |
US6294572B1 (en) | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation | |
AU711228B2 (en) | Production of cefotaxime and new sodium salts | |
US4456753A (en) | Process for the manufacture of highly crystalline sodium cefoperazone | |
KR100384773B1 (en) | (2-Al, 3-S) -hexadecanoyl-4,10-diacetoxy-2 alpha -benzoyloxy-5beta, 20-epoxy-1,7beta-dihydroxy- -3-benzoylamino-2-hydroxy-3-phenylpropionate trihydrate | |
SK282512B6 (en) | 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-9-oxo-19-nor- cyclopropa[g]tax-11-en-13alpha-yl-(2r,3s)-3-tert-butoxycarbonylam ino-2-hydroxy-3-phenylpropionate dihydrate and its preparation me thod | |
US6150541A (en) | 4,10-β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-9-oxo-19-norcyclopropa[g]t ax-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate dihydrate and its process of preparation | |
HUT77090A (en) | Clavulanic acid salts with a diamino-ether, proces for their production and pharmaceutical compositions containing the same | |
CZ20023723A3 (en) | Clavulanic acid purification process | |
US20020025938A1 (en) | Macrolide intermediates in the preparation of clarithromycin | |
MXPA98004604A (en) | Dihydrate (2r, 3s) -3-ter-butoxicarbonilamino-2-hidroxi-3-fenilpropionato de 4, iobeta-diacetoxi-2alfa-benzoiloxi-5beta, 20-epoxi-1-hidroxi-9-oxo-19-nor- ciclopropa [g] tax-11- en-13alfa-ilo, and its preparation procedure | |
KR960011779B1 (en) | Novel process for preparing crystalline hydrate of cephalosporin | |
WO1998041520A1 (en) | A process for the preparation of furazidin | |
WO1992019599A1 (en) | Process for the purification of lofepramine by crystallisation | |
DE1445411A1 (en) | Process for the production of yohimba derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20121209 |